Onkologie. 2016:10(4):181-184 | DOI: 10.36290/xon.2016.039
Malignant tumors of the thyroid gland by oncologist - systemic treatment
- Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
Malignant tumors of the thyroid gland are relatively rare, their incidence is 36–60 cases per 1 million people (i.e. 0.5–1 % of all
malignant tumors). Anyway, an escalating incidence has been reported recently. It comprises variable groups of tumors with different
biological activity. They are more frequent in women than in men. The tumors are usually divided into several histological
categories: differentiated thyroid cancer DTC; (papillary – PTC, follicular – FTC and Hürthle cell carcinoma), medullary thyroid cancer
– MTC and anaplastic thyroid cancer – ATC. Lymphomas, sarcomas and metastatic lesions of other types of cancer can be found in
the thyroid gland very rarely. The article gives an overview of systemic treatment of different histological types of thyroid cancer:
chemotherapy, radiotherapy and targeted treatment and indications of these treatment modalitites in particular tumor types.
Keywords: thyroid cancer, chemotherapy, radiotherapy, targeted treatment
Published: August 1, 2016 Show citation
References
- Vlček P, Neumann J. Karcinom štítné žlázy. Maxdorf 2002.
- Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428.
Go to original source... 
Go to PubMed... - National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology [online], 2016, http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf>
- Pacini F, Castagna MG, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2012; 23(Supp 7): vii110-vii119. Go to original source... Go to PubMed...
- Cooper DS, Doherty GM, Haugen BR, et al. And the American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-214. Go to original source... Go to PubMed...
- Hynková L, Šlampa P, a kol. Radiační onkologie - učební texty. MOÚ 2009: 85-86.
- Brose MS, Nutting CM, Jarzab B, et al. On behalf of the DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014; 384(9940): 319-328. Go to original source...
- Schulmberger M, Makoto Tahara, Wirth Lori J, et al. Lenvatinib versus Placebo in radioiodine-Refractory Thyroid Cancer. N Engl J Med 2015; 372: 621-630. Go to original source...
- Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in Progressive Medullary Thyroid Cancer. JCO.2013 Sep;10.1200/JCO.2012.48.4659. Go to original source...
- Wells SA, Jr, Robinson BG, Gagel RF, et al. Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. JCO. 2012 Jan; 30(2): 134-140. Go to original source...
- Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012 Nov;22(11): 1104-39. doi: 10.1089/thy.2012.0302. Go to original source... Go to PubMed...
- Modrá kniha České onkologické společnosti, www.linkos.cz
- Durante C, et al. J Clin Endocrinol Metab. 2006; 91(8): 2892-2899. Go to original source...
- Pfister DG, et al. J Clin Oncol 2008; 26(29): 4701-4704. Go to original source...